Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632521 | 0.90 | TRPV3 (0.41) | TRPV3MRGPRX4 | |
| SCHEMBL16632462 | 0.82 | TTR (0.40) | — | |
| SCHEMBL3903859 | 0.77 | TRPV3 (0.40) | PTGER1CYP2C9TRPV3MRGPRX4 | |
| SCHEMBL3897518 | 0.76 | TLR9 (0.41) | PTGER1CYP2C9MRGPRX4 | |
| SCHEMBL15590169 | 0.75 | NPC1 (0.49) | PTGER1CYP2C9TRPV3 | |
| SCHEMBL16632378 | 0.75 | L3MBTL1 (0.42) | — | |
| SCHEMBL16632578 | 0.75 | TRPV3 (0.47) | PTGER1CYP2C9TRPV3MRGPRX4 | |
| SCHEMBL18474166 | 0.72 | SRD5A1 (0.55) | MRGPRX4 | |
| SCHEMBL16632354 | 0.72 | BRD4 (0.38) | PTGER1CYP2C9TRPV3MRGPRX4 | |
| SCHEMBL3175931 | 0.72 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | PTGER1 2498/4885CYP2C9 1797/4885TRPV3 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.